Results 21 to 30 of about 46,143 (249)
Blood Advances, 2021 The efficacy and safety of caplacizumab in individuals with acquired thrombotic thrombocytopenic purpura (aTTP) have been established in the phase 2 TITAN and phase 3 HERCULES trials. Integrated analysis of data from both trials was conducted to increase
F. Peyvandi +11 more
semanticscholar +1 more source
Thrombotic thrombocytopenic purpura: a new menace after COVID bnt162b2 vaccine
International journal of hematology, 2021 Thrombotic thrombocytopenic purpura (TTP) is a known menace in hematology and is quite rare in practice with known triggers. Lately, in the COVID-19 pandemic, hematology has seen a new pathology amongst which TTP associated with COVID-19 messenger RNA ...
S. H. Waqar, A. Khan, S. Memon
semanticscholar +1 more source
Annual Incidence and Severity of Acute Episodes in Hereditary Thrombotic Thrombocytopenic Purpura.
Blood, 2021 Hereditary thrombotic thrombocytopenic purpura (hTTP) is a rare thrombotic microangiopathy characterized by severe congenital ADAMTS13 deficiency and recurring acute episodes causing morbidity and premature death.
E. Tarasco +17 more
semanticscholar +1 more source
ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura
Journal of Thrombosis and Haemostasis, 2020 Despite an increase in our understandings of pathogenesis of thrombotic thrombocytopenic purpura (TTP), the approaches for initial diagnosis and management of TTP vary significantly.
X. L. Zheng +13 more
semanticscholar +1 more source
ISTH guidelines for treatment of thrombotic thrombocytopenic purpura
Journal of Thrombosis and Haemostasis, 2020 Despite advances in treatment options for thrombotic thrombocytopenic purpura (TTP), there are still limited high quality data to inform clinicians regarding its appropriate treatment.
X. L. Zheng +13 more
semanticscholar +1 more source
Blood Advances, 2020 Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare but life-threatening condition. In 2018, the nanobody caplacizumab was approved for the treatment of adults experiencing an acute episode of aTTP, in conjunction with plasma exchange (PEX) and
L. Völker +41 more
semanticscholar +1 more source
eJHaem, 2021 Acquired thrombotic thrombocytopenic purpura is characterized by the microvascular aggregation of platelets and microangiopathic hemolytic anemia causing ischemia of multiple organs including the brain mainly and less likely the kidney and the heart. The
M. Al‐Ahmad +2 more
semanticscholar +1 more source
Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura
New England Journal of Medicine, 2019 BACKGROUND In acquired thrombotic thrombocytopenic purpura (TTP), an immune‐mediated deficiency of the von Willebrand factor–cleaving protease ADAMTS13 allows unrestrained adhesion of von Willebrand factor multimers to platelets and microthrombosis ...
M. Scully +12 more
semanticscholar +1 more source
Thrombotic thrombocytopenic purpura [PDF]
The Journal of the American Osteopathic Association, 1989 Once formerly thought to be a rare disorder, thrombotic thrombocytopenic purpura (TTP) is becoming increasingly recognized. It is characterized by a pentad of clinical findings, including microangiopathic hemolytic anemia, thrombocytopenic purpura, neurologic and renal abnormalities, and fever.
openaire +3 more sources
Clinical surveillance of thrombotic microangiopathies in Scotland, 2003-2005 [PDF]
, 2007 The prevalence, incidence and outcomes of haemolytic uraemic syndrome (HUS) and thrombotic thrombocytopaenic purpura (TTP) are not well established in adults or children from prospective studies. We sought to identify both outcomes and current management
D. YOUNG +8 more
core +2 more sources